Loh F Ellen, Stuart Bruce, Sturpe Deborah, Davidoff Amy, Onukwugha Eberechukwu, Hochberg Marc
Sr Care Pharm. 2019 Feb 1;34(2):109-126. doi: 10.4140/TCP.n.2019.109.
: This study compares patterns of evidence-based osteoporosis medication use among females in community and long-term care settings enrolled in Medicare Part D.
: Pooled cross-sectional study.
: Medicare beneficiaries enrolled in Medicare Parts A and B, and Part D stand-alone prescription drug plans from January 1, 2006, through December 31, 2008, or death.
: Female Medicare Part D enrollees 70 years of age and older with osteoporosis or prior hip fracture.
: NA.
: Use of bisphosphonates, calcitonin, teriparatide, and raloxifene was tracked by residential status over the three-year period.
: The study sample comprised 96,408 female Part D enrollees with osteoporosis. Prevalence of evidence-based medication use was 42.3% in 2006 and dropped slightly to 40.4% in 2008. In unadjusted comparisons, long-term care residents were significantly less likely to use any osteoporosis medication compared with community dwellers (40.6% vs. 53.1%). After adjustment for differences in individual characteristics, utilization was still lower among long-term care residents (relative risk [RR] = 0.89, 95% confidence interval [CI] 0.87-0.91). Bisphosphonates were the top choice among medication users, but were prescribed much less often to long-term care residents (RR = 0.79, 95% CI 0.75-0.83) compared with community residents.
: Prevalence of evidence-based osteoporosis medication use is low in older women enrolled in Part D whether community-dwelling or long-term care residents, but long-term nursing facility residents are more likely to be treated with nonbisphosphonates. Many events that may affect osteoporosis medication use occurred after 2008; therefore, future studies using more recent data are warranted to examine osteoporosis medication use after 2008.
本研究比较了参加医疗保险D部分的社区和长期护理机构中的女性使用循证骨质疏松症药物的模式。
汇总横断面研究。
2006年1月1日至2008年12月31日期间参加医疗保险A部分和B部分以及D部分独立处方药计划的医疗保险受益人,或直至死亡。
70岁及以上患有骨质疏松症或既往有髋部骨折的女性医疗保险D部分参保者。
无。
在三年期间,根据居住状况追踪双膦酸盐、降钙素、特立帕肽和雷洛昔芬的使用情况。
研究样本包括96408名患有骨质疏松症的女性D部分参保者。循证药物使用的患病率在2006年为42.3%,在2008年略有下降至40.4%。在未经调整的比较中,与社区居民相比,长期护理机构居民使用任何骨质疏松症药物的可能性显著降低(40.6%对53.1%)。在调整个体特征差异后,长期护理机构居民的使用率仍然较低(相对风险[RR]=0.89,95%置信区间[CI]0.87-0.91)。双膦酸盐是用药者的首选,但与社区居民相比,长期护理机构居民的处方率要低得多(RR=0.79,95%CI0.75-0.83)。
无论是社区居民还是长期护理机构居民,参加D部分的老年女性循证骨质疏松症药物使用的患病率都很低,但长期护理机构居民更有可能接受非双膦酸盐治疗。许多可能影响骨质疏松症药物使用的事件发生在2008年之后;因此,有必要使用更新的数据进行未来研究,以检查2008年之后的骨质疏松症药物使用情况。